Hypertension and use of bevacizumab among patients treated in community settings.
Plain-language summary
Using CancerLinQ Discovery, a real-world dataset drawn from US electronic health records, the researchers examined hypertension and blood pressure patterns among breast cancer and lung cancer patients treated with bevacizumab. Among 1,941 breast cancer and 4,590 lung cancer patients treated from 2005 to 2017, more than half had hypertension at baseline, and a large share saw their systolic blood pressure rise by at least 10 mmHg within 120 days of starting bevacizumab, including many who began with normal blood pressure. This is a conference abstract describing real-world blood pressure changes associated with bevacizumab in community-treated patients.
Read the full paper (DOI: 10.1200/JCO.2019.37.15_suppl.e18279).
This is a plain-language summary written for discoverability; the authoritative version is the published paper. Part of Travis Osterman's peer-reviewed publications.